ID: ALA331314

Max Phase: Preclinical

Molecular Formula: C14H15N5OS

Molecular Weight: 301.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1Sc1[nH]c2nc(N)nc(N)c2c1C

Standard InChI:  InChI=1S/C14H15N5OS/c1-7-10-11(15)17-14(16)19-12(10)18-13(7)21-9-6-4-3-5-8(9)20-2/h3-6H,1-2H3,(H5,15,16,17,18,19)

Standard InChI Key:  WRYKYFPFYKSJNN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 301.38

Molecular Weight (Monoisotopic): 301.0997

AlogP: 2.59

#Rotatable Bonds: 3

Polar Surface Area: 102.84

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.29

CX Basic pKa: 8.36

CX LogP: 2.77

CX LogD: 1.79

Aromatic Rings: 3

Heavy Atoms: 21

QED Weighted: 0.69

Np Likeness Score: -0.64

References

1. Gangjee A, Lin X, Queener SF..  (2004)  Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.,  47  (14): [PMID:15214795] [10.1021/jm0306327]

2. Gangjee A, Lin X, Biondo LR, Queener SF..  (2010)  CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified cross-validated r(2)-guided region selection (q(2)-GRS) routine and its initial application.,  18  (4): [PMID:20117005] [10.1016/j.bmc.2009.12.066]

3. Shah K, Lin X, Queener SF, Cody V, Pace J, Gangjee A..  (2018)  Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.,  26  (9): [PMID:29691153] [10.1016/j.bmc.2018.04.032]

Source

Source(1):

• Scientific Literature